



EB-C3^{DR} Delayed Release

Welcome to EBM Medical. We provide high quality medical food formulations using USP grade active pharmaceutical ingredients supported by evidence-based medicine to address chronic metabolic deficiencies.

Your healthcare provider has prescribed EB-C3^{DR} for the metabolic management of deficiencies associated with cognitive disorders.

EB-C3^{DR} Delayed Release*

L-methylfolate Calcium6 mg
Methylcobalamin.....2 mg
N Acetyl L-Cysteine600 mg
Pyridoxal 5'-Phosphate 1.7 mg

Dosage:

Adult dose is 1 capsule daily or as directed by physician.



Each vegan capsule is allergen and dye free.

Therapeutic Active Pharmaceutical Ingredient Guide¹⁻⁴

ACTIVE INGREDIENT	DESCRIPTION
L-methylfolate Calcium [active folate (pure crystalline)]	+ Acetylcholine, a natural substance in the brain associated with memory
Methylcobalamin [active Vitamin B ₁₂]	+ Methylation, a process in the brain required for neuroprotection
N Acetyl L-Cysteine [antioxidant]	- Substances harmful to the brain
Pyridoxal 5'- Phosphate [active Vitamin B ₆]	+ Methylation, a process in the brain required for neuroprotection

+ increase - decrease



Manufactured in compliance with current Good Manufacturing Practices. [cGMP].
*Products feature delayed-release capsules for targeted delivery to promote tolerability.

EBM Medical Contact Information

Phone: 1-844-360-4095
Email: support@EBMmedical.com
Website: EBMmedical.com



FREQUENTLY ASKED QUESTIONS

What is EB-C3^{DR}?⁵

EB-C3^{DR} is an oral capsule classified as a medical food, a unique category regulated by the FDA. Medical foods address the metabolic deficiencies associated with diseases to help manage chronic conditions, including Mild Cognitive Impairment (MCI). Medical foods are intended for use under medical supervision.

What should I expect?^{1-4,6}

Metabolic deficiencies in the brain have been identified as an independent risk factor for memory loss, as they reduce the substances responsible for neuroprotection.

The unique active ingredients in EB-C3^{DR} provide necessary nutrients that support brain nourishment and protection.

How does EB-C3^{DR} compare to over-the-counter products?⁷

Traditional folic acid must be broken down (activated) in the body before it can be used. Up to 50% of people have a compromised ability to complete this activation, due to a genetic variant in the enzyme responsible for folate metabolism called MTHFR c677t. **EB-C3^{DR} features Biofolate[®], a form of folate, which is unaffected by the MTHFR c677t variant.**

What are the side effects with EB-C3^{DR}?

The active pharmaceutical ingredients in EB-C3^{DR} are well tolerated and allergen, gluten and dye free. The most common complaints include mild upset stomach. If you experience this, try taking the capsules with food. If the problem persists, consult your provider.

How do I refill my order?

Simply call or email EBM Medical at 636-614-3152 or support@ebmmedical.com. You may also opt in for the EBM Convenience Fill program where EBM will automatically refill your order 10 days prior to your last dosage. Do not stop taking your medical food formula without talking to your healthcare provider.

REFERENCES

1. Chan A et al. Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionine. *J Nutr Health Aging*. 2008 Apr;12(4):252-61.
2. de Jager CA et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *Int J Geriatr Psychiatry*. 2012; 27: 592-600.
3. Durga J et al. Effect of 3-Year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomized, double blind, controlled trial. *Lancet* 2007; 369: 208-216.
4. Hara Y et al. Evaluation of the neuroprotective potential of NAC for Prevention and Treatment of Cognitive Aging and Dementia. *J Prev Alz Dis* 2017;4(3):201-206.
5. <http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/ucm054.htm>. Accessed May 23, 2019.
6. Smith DA et al. Homocysteine and Dementia: An International Consensus Statement. *Journal of Alzheimer's Disease*. 62 (2018) 561-570.
7. Klerk M et al. MTHFR 677CT polymorphism and risk of coronary heart disease: a meta-analysis. *JAMA*. 2002 Oct 23-30;288(16):2023-31.